Healthcare provider profile · identity verified

Judith A Devorak

Nurse Practitioner · STEWARTVILLE, MN · NPI 1760422927

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	231	66
Atorvastatin Calcium	Atorvastatin Calcium	158	44
Rosuvastatin Calcium	Rosuvastatin Calcium	157	47
Levothyroxine Sodium	Levothyroxine Sodium	147	29
Amlodipine Besylate	Amlodipine Besylate	138	42
Omeprazole	Omeprazole	132	29
Metoprolol Succinate	Metoprolol Succinate	105	31
Losartan Potassium	Losartan Potassium	102	32
Sertraline Hcl	Sertraline Hcl	92	20
Gabapentin	Gabapentin	86	22
Famotidine	Famotidine	81	23
Eliquis	Apixaban	79	15
Tramadol Hcl	Tramadol Hcl	68	21
Simvastatin	Simvastatin	61	19
Metformin Hcl	Metformin Hcl	58	16
Furosemide	Furosemide	56	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	54	suppressed
Potassium Chloride	Potassium Chloride	53	19
Spironolactone	Spironolactone	52	12
Metformin Hcl Er	Metformin Hcl	49	16
Alendronate Sodium	Alendronate Sodium	47	14
Trazodone Hcl	Trazodone Hcl	44	16
Hydrochlorothiazide	Hydrochlorothiazide	43	15
Oxycodone Hcl	Oxycodone Hcl	41	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	39	15
Quetiapine Fumarate	Quetiapine Fumarate	39	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	38	20
Ventolin Hfa	Albuterol Sulfate	38	18
Duloxetine Hcl	Duloxetine Hcl	37	13
Fluconazole	Fluconazole	35	12
Tamsulosin Hcl	Tamsulosin Hcl	34	11
Amoxicillin	Amoxicillin	33	25
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Montelukast Sodium	Montelukast Sodium	31	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Torsemide	Torsemide	28	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	27	suppressed
Lorazepam	Lorazepam	26	suppressed
Ropinirole Hcl	Ropinirole Hcl	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Glipizide	Glipizide	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Carvedilol	Carvedilol	21	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	21	suppressed
Warfarin Sodium	Warfarin Sodium	21	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Symbicort	Budesonide/Formoterol Fumarate	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Allopurinol	Allopurinol	19	suppressed
Naproxen	Naproxen	19	suppressed
Prednisone	Prednisone	19	11
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Atrovent Hfa	Ipratropium Bromide	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	17	11
Nystatin	Nystatin	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Spiriva Handihaler	Tiotropium Bromide	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	15
Spiriva Respimat	Tiotropium Bromide	15	suppressed
Atenolol	Atenolol	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Cephalexin	Cephalexin	14	12
Lamotrigine	Lamotrigine	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Topiramate	Topiramate	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Methylprednisolone	Methylprednisolone	13	11
Diazepam	Diazepam	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Saxagliptin Hcl	Saxagliptin Hcl	12	suppressed
Cefdinir	Cefdinir	11	suppressed
Nyamyc	Nystatin	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error